53
Participants
Start Date
July 22, 2021
Primary Completion Date
October 16, 2023
Study Completion Date
October 16, 2023
Tafamidis
61 mg, once daily, oral administration, for 12 months.
Peking University First Hospital, Beijing
Peking University Third Hospital, Beijing
Peking Union Medical College Hospital, Beijing
The First Affiliated Hospital of Dalian Medical University, Dalian
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
The Second Xiangya Hospital of Central South University, Changsha
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan
West China Hospital of Sichuan University, Chengdu
Lead Sponsor
Pfizer
INDUSTRY